333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer

Autor:	Hannah M. Linden, Simon Lord, S. Cartot-Cotton, Vasiliki Pelekanou, A. Gosselin, M. Campone, Sarat Chandarlapaty, Patrick Neven, Aditya Bardia, Valentina Boni, Peter Kabos, Marina Celanovic
Rok vydání:	2021
Předmět:	Postmenopausal women Phase i ii Oncology business.industry Advanced breast medicine Cancer research Estrogen receptor Cancer Hematology medicine.disease business Human Epidermal Growth Factor Receptor 2
Zdroj:	Annals of Oncology. 32:S511-S512
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.616
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2dc19defaaeca4a92638bfecf62dc907 https://doi.org/10.1016/j.annonc.2021.08.616 Zobrazit plný text záznamu